Data / Drug companies / Guangzhou Yapheon Health Industry Co., Ltd.
Guangzhou Yapheon Health Industry Co., Ltd.: 7 products in the FDA NDC directory, labeler code 87582
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Guangzhou Yapheon Health Industry Co., Ltd. (labeler code 87582) lists 7 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 7 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on June 27, 2026.
The request: Watch Guangzhou Yapheon Health Industry Co., Ltd. (FDA labeler code 87582): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 87582
- Products in commercial distribution
- 7
- Packages
- 8
- Finished drugs by generic name
- 2
- Prescription products
- 0
- Over the counter products
- 7
- Flagged as original packager
- 7 of 7 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- April 11, 2026
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 7 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 7 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Salicylic acid | 2 | 330 |
| Allantoin | 1 | 31 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Cream | 4 | 57.1% |
| Paste | 1 | 14.3% |
| Patch | 1 | 14.3% |
| Spray | 1 | 14.3% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Orlaskin hydrogel eye mask | 87582-007 | Patch | Over the counter monograph drugs | June 27, 2026 |
| Orlaskin salicylic acid acne treatment pads | 87582-006 | Paste | Over the counter monograph drugs | June 27, 2026 |
| ORLASKIN ACNE Treatment | 87582-005 | Cream | Over the counter monograph drugs | June 27, 2026 |
| Orlaskin hydrating sunscreen spf 50 | 87582-004 | Spray | Over the counter monograph drugs | June 27, 2026 |
| ORLASKIN SPF50 Antioxidant SoothingComplex Sunscreen | 87582-003 | Cream | Over the counter monograph drugs | June 26, 2026 |
| Inflair Elevate SPF15 Moisturizer | 87582-002 | Cream | Over the counter monograph drugs | June 7, 2026 |
| Trust md spf30 stem cell face | 87582-001 | Cream | Over the counter monograph drugs | April 11, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.